3 to 4 million patients fit the entry criteria Multicenter Autonomic Defibrillator Implantation Trial II (MADIT II): Background MADIT & Multicenter Unsustained Tachycardia Trial (MUSTT): Demonstrated a benefit from ICD implantation in patients with CAD, reduced ventricular function, unsustained ventricular tachycardia, and inducible ventricular tachycardia on EP testing. In MADIT II: No EP study required, inclusion criteria included a prior MI at least 30 days previous to implantation, and EF of 30% or less. MADITT randomized 1232 patients from 71 US centers and 5 European centers to receive either an ICD, or to continue on conventional medical therapy 3 to 4 million patients fit the entry criteria 400,000 new cases annually

Multicenter Autonomic Defibrillator Implantation Trial II (MADIT II) 2,118 patients with anterior infarction, double blind randomized trial High Dose Adenosine 70 µg/kg/min for 3 (n Low Dose Adenosine 50 µg/kg/min for 3 hours Placebo + + + Thrombolysis or PCI Thrombolysis or PCI Thrombolysis or PCI Infarct Size 120 –168 hours Death/CHF at 6 months